Abstract
N-BP, rapamycin and its derivatives have been originally developed respectively as anti-resorptive and anti-fungal agents. In fact, in vitro and in vivo experiments demonstrated that these compounds are multi-functional molecules exerting their effects on tumour cell growth and bone remodelling. The major challenge in treating cancer relates to mutations in key genes such as p53, Rb or proteins affecting caspase signalling carried by many tumour cells. Whether nitrogen containing bisphosphonates (N-BP) are potent bone inhibitors, they also inhibit tumour cell proliferation and increase atypical apoptosis of bone tumour cells regardless of the p53 and Rb status. N-BP may be then considered as effective therapeutic agents in clinical trials of bone tumours. Rapamycin and its derivatives inhibit mTOR dependent mRNA translation both in osteoclasts and tumour cells. Cellular physiological mechanisms regulated by mTOR integrate many environmental parameters including growth factors, hormones, cytokines, amino acids, energy availability and cellular stresses that are coupled with cell cycle progression and cell growth. Rapamycin and its derivatives as well as N-BP must be considered as bi-(multi) functional molecules affecting simultaneously bone and tumour metabolisms. The present survey describes these two molecular families and discusses their therapeutic interests for primary bone tumours and bone metastases.
Keywords: Rapamycin, bisphosphonate, bone, osteolysis, bone remodelling, primary bone tumours, metastases
Current Medicinal Chemistry
Title: mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours
Volume: 14 Issue: 13
Author(s): Benjamin Ory, Gatien Moriceau, Francoise Redini and Dominique Heymann
Affiliation:
Keywords: Rapamycin, bisphosphonate, bone, osteolysis, bone remodelling, primary bone tumours, metastases
Abstract: N-BP, rapamycin and its derivatives have been originally developed respectively as anti-resorptive and anti-fungal agents. In fact, in vitro and in vivo experiments demonstrated that these compounds are multi-functional molecules exerting their effects on tumour cell growth and bone remodelling. The major challenge in treating cancer relates to mutations in key genes such as p53, Rb or proteins affecting caspase signalling carried by many tumour cells. Whether nitrogen containing bisphosphonates (N-BP) are potent bone inhibitors, they also inhibit tumour cell proliferation and increase atypical apoptosis of bone tumour cells regardless of the p53 and Rb status. N-BP may be then considered as effective therapeutic agents in clinical trials of bone tumours. Rapamycin and its derivatives inhibit mTOR dependent mRNA translation both in osteoclasts and tumour cells. Cellular physiological mechanisms regulated by mTOR integrate many environmental parameters including growth factors, hormones, cytokines, amino acids, energy availability and cellular stresses that are coupled with cell cycle progression and cell growth. Rapamycin and its derivatives as well as N-BP must be considered as bi-(multi) functional molecules affecting simultaneously bone and tumour metabolisms. The present survey describes these two molecular families and discusses their therapeutic interests for primary bone tumours and bone metastases.
Export Options
About this article
Cite this article as:
Ory Benjamin, Moriceau Gatien, Redini Francoise and Heymann Dominique, mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours, Current Medicinal Chemistry 2007; 14 (13) . https://dx.doi.org/10.2174/092986707780831159
DOI https://dx.doi.org/10.2174/092986707780831159 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contributions of Medicinal Chemistry During the Pandemic of Covid-19
Current Topics in Medicinal Chemistry Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine
Current Topics in Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Probiotics and Immune Regulation of Inflammatory Bowel Diseases
Current Drug Targets - Inflammation & Allergy Subcellular Accumulation and Modification of Pharmaceutical Proteins in Different Plant Tissues
Current Pharmaceutical Design Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease
Current Neuropharmacology Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research Meet Our Editorial Board Member:
Current Pharmaceutical Biotechnology Controlling Apoptosis by Inhibition of Caspases
Current Medicinal Chemistry Screening of Natural Lead Molecules Against Putative Molecular Targets of Drug-resistant Cryptococcus spp: An Insight from Computer-aided Molecular Design
Current Topics in Medicinal Chemistry NS5B RNA Dependent RNA Polymerase Inhibitors: The Promising Approach to Treat Hepatitis C Virus Infections
Current Medicinal Chemistry Targeting Natural Products for the Treatment of COVID-19 – An Updated Review
Current Pharmaceutical Design The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Exposure to Perinatal Infections and Bipolar Disorder: A Systematic Review
Current Molecular Medicine